A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 453 participants.
Also called NCT03175120
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 453 participants
- Sponsor
- Registry
-
NCT03175120
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Hong Kong SAR China
- Registry status
- Completed
Technical summary
Registry record NCT03175120. Randomized; double masking; primary purpose treatment. Start 2017-05-26 (actual); primary completion 2019-03-05 (actual). Results posted on 2020-03-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
- Acronym
- DUAL™ II China
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin degludec/liraglutide
- Intervention (Drug)
- Insulin degludec
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03175120- Content hash
4b87940a4791f5b7d094c728c87245a6d3689951d69a084ab4fc73f8285e5300